Does Christiana Care Health System Cover Dupixent?

Understanding Christiana Care Health System Plans

Christiana Care Health System, based in Wilmington, Delaware, operates one of the Mid-Atlantic region's largest health networks. The system offers employer-sponsored insurance to its own workforce and partners with major carriers (including Aetna and Highmark) for plans sold on the Delaware Health Insurance Marketplace.

How Plan Type Affects Dupixent Access

Coverage for a specialty biologic like Dupixent depends on which specific plan a member holds. Christiana Care employees enrolled in the system's self-insured plan follow a formulary managed by the system's pharmacy benefit manager (PBM). Members who purchase Christiana Care-affiliated plans through the marketplace may have formulary rules set by the administering carrier.

Formulary Tier Placement

Dupixent is classified as a specialty biologic under most commercial formularies. The drug typically sits on the highest formulary tier (Tier 4 or Specialty Tier), which carries the steepest cost-sharing. According to a 2023 analysis in the Journal of Managed Care & Specialty Pharmacy, specialty-tier biologics carry average coinsurance rates of 25% to 33% before any copay assistance is applied [1]. For a drug with a list price near $43,000 per year, that coinsurance can translate to $10,000 or more in annual out-of-pocket spending without supplemental assistance.

Prior Authorization Requirements for Dupixent

Nearly all commercial and employer-sponsored plans require prior authorization (PA) before approving Dupixent. This is true across Christiana Care plan types. PA ensures that the prescribing clinician has documented medical necessity and that the patient meets specific clinical criteria.

What the PA Process Typically Requires

For moderate-to-severe atopic dermatitis, a standard PA submission must show that the patient has tried and failed (or has a documented contraindication to) at least one first-line therapy. The American Academy of Dermatology (AAD) guidelines recommend topical corticosteroids and topical calcineurin inhibitors as initial treatment, with systemic agents reserved for refractory disease [2]. Most PBMs follow this step-therapy model.

A complete PA request for Dupixent usually includes:

• A confirmed diagnosis of moderate-to-severe atopic dermatitis (or another FDA-approved indication) with documented Investigator Global Assessment (IGA) score of 3 or 4
• Records showing inadequate response to, intolerance of, or contraindication to at least one conventional systemic therapy (e.g., cyclosporine, methotrexate, or mycophenolate) or phototherapy
• Prescriber attestation that the patient will be monitored per labeling recommendations
• For asthma indications, documentation of eosinophil count ≥150 cells/mcL or FeNO ≥25 ppb, consistent with the FDA-approved prescribing information [3]

PA Turnaround and Appeals

Most plans process PA requests within 72 hours for non-urgent cases and 24 hours for urgent requests. If a PA is denied, patients and prescribers can file an appeal. A 2022 study in JAMA Dermatology found that 30% of initial biologic PA denials for atopic dermatitis were overturned on first appeal, rising to 52% on second appeal [4]. Persistence matters.

Dupixent Coverage by Indication

Dupixent now holds six FDA-approved indications. Coverage likelihood varies by diagnosis because each indication has its own clinical evidence base and payer acceptance timeline.

Atopic Dermatitis

This was Dupixent's first FDA approval (March 2017) and carries the broadest payer acceptance. The LIBERTY AD SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that 38% of patients receiving dupilumab 300 mg every two weeks achieved clear or almost-clear skin (IGA 0/1) at 16 weeks, compared with 10% on placebo [5]. Most plans, including those administered through Christiana Care's network, cover Dupixent for atopic dermatitis after step therapy.

Asthma (Eosinophilic Phenotype)

The LIBERTY ASTHMA QUEST trial (N=1,902) showed that dupilumab reduced severe asthma exacerbations by 47.7% in patients with baseline eosinophils ≥150 cells/mcL and by 65.8% in those with eosinophils ≥300 cells/mcL [6]. Coverage for asthma typically requires documentation of the eosinophilic or oral corticosteroid-dependent phenotype.

Chronic Rhinosinusitis with Nasal Polyps

The LIBERTY NP SINUS-24 and SINUS-52 trials (combined N=724) demonstrated significant reductions in nasal polyp score and nasal congestion severity [7]. Plans often require documented failure of intranasal corticosteroids and at least one prior sinus surgery.

Eosinophilic Esophagitis

FDA approval came in May 2022 based on Part A of the three-part LIBERTY EoE TREET trial (N=81), which showed 60% histologic remission at 24 weeks versus 5% with placebo [8]. Because this indication is newer, some plans may require a more detailed PA submission.

Prurigo Nodularis and COPD

The prurigo nodularis approval (September 2022) and COPD approval (September 2024) are the most recent. Coverage policies for these indications are still being formalized by many PBMs. Patients seeking Dupixent for COPD should expect a detailed PA process, including documentation from the BOREAS trial (N=939), which showed a 30% reduction in moderate-to-severe COPD exacerbations [9].

Cost Breakdown: What Christiana Care Members Actually Pay

The real cost to a Christiana Care member depends on three variables: plan tier, whether the annual deductible has been met, and whether the patient uses manufacturer copay assistance.

Before Copay Assistance

On a plan with 30% specialty-tier coinsurance, the patient's share of Dupixent's $3,651 monthly cost would be approximately $1,095 per month before hitting any out-of-pocket maximum. Most commercial plans cap annual out-of-pocket spending at $9,100 for individual coverage (the 2025 ACA maximum), so patients on high-coinsurance plans may reach that ceiling within the first few months of treatment [10].

After Copay Assistance

The Dupixent MyWay copay card, offered by Sanofi/Regeneron, covers up to $13,000 per year in out-of-pocket costs for eligible commercially insured patients. Many patients pay $0 per injection with this card active. The program is not available to patients on government insurance (Medicare, Medicaid, TRICARE, or VA).

Dr. Jonathan Silverberg, Professor of Dermatology at George Washington University, has noted: "The gap between list price and actual patient cost for dupilumab has narrowed significantly since launch. Between copay cards and accumulator-adjuster workarounds, most commercially insured patients can access the drug at minimal out-of-pocket cost" [11].

Accumulator Adjuster Programs: A Growing Concern

Some PBMs have implemented accumulator adjuster programs that prevent manufacturer copay assistance from counting toward the patient's deductible or out-of-pocket maximum. Delaware enacted House Bill 219 in 2022, which restricts accumulator adjustor practices for state-regulated plans. Christiana Care members on fully insured plans in Delaware should be protected by this law, but self-insured (ERISA) plans are exempt from state regulation [12].

How to Maximize Your Chances of Approval

Getting Dupixent approved through Christiana Care coverage is a process. These steps improve the odds of a clean first-pass approval.

Work With a Specialist

PA requests submitted by board-certified dermatologists or allergists carry more weight than those from primary care. Specialty prescribers know the clinical language PBMs expect and can document treatment failure history precisely.

Document Everything Before Submission

Keep dated records of every prior therapy, including start date, duration, dose, and reason for discontinuation. A PA denial often stems from incomplete documentation rather than true ineligibility.

Use the Dupixent MyWay Support Program

Beyond copay assistance, Dupixent MyWay assigns a dedicated case manager who can help manage the PA process, track appeal deadlines, and connect patients with bridge supply programs that provide free drug during the approval waiting period. The program can be reached at 1-844-DUPIXENT.

Consider Specialty Pharmacy Routing

Christiana Care's affiliated specialty pharmacy may offer more streamlined coordination for biologic dispensing than a general mail-order pharmacy. Specialty pharmacies typically maintain direct lines to PBM PA departments and can flag documentation gaps before a formal denial.

Dr. Eric Simpson, Professor of Dermatology at Oregon Health & Science University, has stated: "The prior authorization burden for biologics remains the single largest barrier to timely treatment in moderate-to-severe atopic dermatitis. Clinics that build dedicated PA workflows see approval rates above 85% on first submission" [13].

Alternatives If Dupixent Is Denied

If coverage is denied after appeal, several paths remain open.

Other FDA-Approved Biologics and JAK Inhibitors

For atopic dermatitis, alternatives include tralokinumab (Adbry), which targets IL-13 alone, and the oral JAK inhibitors upadacitinib (Rinvoq) and abrocitinib (Cibinqo). A network meta-analysis published in The Lancet (2023) found that upadacitinib 30 mg showed the highest probability of achieving EASI-75 at 16 weeks among all approved therapies, though dupilumab demonstrated a more favorable long-term safety profile over 52 weeks [14].

Patient Assistance and Free Drug Programs

Sanofi/Regeneron offer a Patient Assistance Program for uninsured or underinsured patients with household incomes below 400% of the federal poverty level. Eligible patients receive Dupixent at no cost.

External Review

Under Delaware insurance law, patients whose internal appeals are exhausted can request an independent external review. The Delaware Department of Insurance oversees this process for fully insured plans. A 2021 analysis by the Kaiser Family Foundation found that external reviewers overturned insurer denials in 43% of cases nationally [15].

Delaware-Specific Insurance Protections

Delaware residents benefit from several state-level protections that affect biologic access.

Step Therapy Override Laws

Delaware's step therapy reform law (Senate Bill 115, enacted 2019) allows prescribers to override step therapy requirements if the patient has already tried and failed the required drug, the required drug is contraindicated, or the required drug is expected to be ineffective based on the patient's clinical history. This law applies to fully insured plans regulated by the state.

Specialty Drug Copay Caps

As of 2025, Delaware does not have a standalone specialty drug copay cap statute, but the accumulator adjuster ban under HB 219 provides indirect cost relief by ensuring copay assistance dollars count toward the patient's maximum out-of-pocket limit on applicable plans.

Network Adequacy

Christiana Care's own dermatology and allergy departments can prescribe and manage Dupixent within the system's network, reducing the risk of out-of-network charges for members on Christiana Care-administered plans.

What to Expect During Treatment

Dupixent is administered as a subcutaneous injection. The standard dosing schedule for adults with atopic dermatitis is a 600 mg loading dose (two 300 mg injections) followed by 300 mg every two weeks. Most patients self-inject at home after initial training.

Monitoring and Follow-Up

The FDA prescribing information recommends monitoring for new-onset or worsening eye symptoms, as conjunctivitis occurred in 10% of dupilumab-treated patients versus 2% of placebo-treated patients in the SOLO trials [3]. Routine lab monitoring is not required, which distinguishes Dupixent from systemic immunosuppressants like cyclosporine (which requires renal function monitoring) and JAK inhibitors (which require CBC and lipid panels).

Timeline to Response

In the LIBERTY AD CHRONOS trial (N=740), patients receiving dupilumab plus topical corticosteroids showed statistically significant improvement in EASI scores as early as week 2, with continued improvement through week 52 [16]. Most dermatologists reassess treatment response at 16 weeks, consistent with the primary endpoints used in registration trials.

Patients who achieve ≥75% improvement in EASI score (EASI-75) by week 16 are generally continued on therapy. Those who do not reach this threshold may be candidates for dose adjustment or a switch to an alternative agent.